LifeStance (LFST) Files Form 144 for 2.47M-Share Sale on NASDAQ
Rhea-AI Filing Summary
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 2,471,741 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $13,372,118.81. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The securities to be sold were originally acquired on 06/10/2021 in pre-IPO transactions, with 14,183,201 shares reported as acquired at that time. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
Positive
- Detailed transaction disclosure including number of shares, aggregate market value, broker, exchange, and approximate sale date
- Acquisition history provided: securities were acquired on 06/10/2021 in pre-IPO transactions and amount acquired is reported
- Certification of no undisclosed material adverse information by the filer is included
Negative
- Planned sale of 2,471,741 shares is disclosed which could increase available shares in the market (aggregate value $13,372,118.81)
- No information on any trading plan dates is provided in the remarks to indicate a Rule 10b5-1 plan adoption date
Insights
TL;DR: Form 144 discloses a planned sale of 2.47M LFST shares valued at $13.37M; transaction details and broker are provided.
The filing gives clear transaction specifics: number of shares, aggregate market value, broker (Morgan Stanley & Co. LLC), exchange (NASDAQ) and an approximate sale date. The securities were acquired in a pre-IPO transaction on 06/10/2021 and a substantially larger block (14,183,201 shares) was originally acquired, indicating the filer still holds a meaningful position relative to the shares being offered.
Impact to the market depends on execution and demand; the Form 144 itself is a routine regulatory notice that enables transparent secondary sales by insiders or early holders.
TL;DR: The notice documents an insider-related sale plan with standard certifications about material information.
The filing includes the required representation that the filer is not aware of undisclosed material adverse information and notes the pre-IPO origin of the holdings. It lists no recent sales in the past three months. From a governance perspective, the filing follows disclosure norms and identifies the broker and planned sale timing, which helps shareholders assess potential share supply from an insider or large pre-IPO holder.
FAQ
What does LifeStance Health Group (LFST) disclose in this Form 144?
When were the shares being sold originally acquired?
How many shares outstanding does the filing report for LFST?
Who is the broker handling the proposed sale?
Did the filer report any sales of issuer securities in the past three months?